01.03.2018
- The US Food and Drug Administration (FDA) has approved AstraZeneca and MedImmune’s immunotherapy Imfinzi (durvalumab) to treat patients with a certain form of lung cancer. Imfinzi...
01.08.2017
- AstraZeneca has entered into a global collaboration with US drugmaker Merck to develop and commercialize the former’s investigational cancer treatments Lynparza (olaparib) and...
